BioAge Labs, Inc.

Rosen Law Firm filed a class action lawsuit for BioAge Labs, Inc. stock purchasers post-IPO, alleging misleading statements about azelaprag's safety and trial outcomes. Investors may join the lawsuit by March 10, 2025, for potential compensation without upfront fees.

BioAge Labs, Inc. faces a lawsuit from shareholders after discontinuing its STRIDES Phase 2 trial for azelaprag due to safety concerns, causing stock prices to drop from $20.09 to $4.65. Affected investors can seek recovery under federal securities laws through Levi & Korsinsky LLP, a leading securities litigation firm.

Kirby McInerney LLP filed a class action lawsuit for BioAge Labs, Inc. investors, alleging misleading information about its STRIDES Phase 2 trial, discontinued due to safety concerns, causing a 76% stock price drop. Investors have until March 10, 2025, to apply as lead plaintiff.

Bleichmar Fonti & Auld LLP filed a lawsuit against BioAge Labs, Inc. for alleged federal securities law violations. The lawsuit claims BioAge misled investors about the safety and progress of its STRIDES Phase 2 trial for azelaprag, leading to a 76% stock drop after trial discontinuation due to safety concerns.

Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against BioAge Labs, Inc. for alleged Securities Act violations. Investors who purchased BIOA stock post-IPO have until March 10, 2025, to seek lead plaintiff status. The lawsuit claims IPO documents were misleading, leading to a 76% stock drop after discontinuing a drug trial.

Bragar Eagel & Squire, P.C. announced a class action lawsuit against BioAge Labs, Inc. for investors who purchased securities during its IPO. The lawsuit follows BioAge's discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, causing a significant stock price drop. Investors have until March 10, 2025, to apply as lead plaintiff.

Pomerantz LLP investigates BioAge Labs, Inc. for potential securities fraud after its stock price dropped 76.85% following the discontinuation of a Phase 2 study due to liver transaminitis in subjects. BioAge's IPO was at $18.00 per share, but fell to $4.65 after the announcement.

BioAge Labs, Inc. (BIOA) discontinued a Phase 2 study for azelaprag, leading to an 80% stock drop. Hagens Berman investigates BioAge's disclosures on azelaprag's safety. Investors with significant losses are encouraged to contact Hagens Berman. Whistleblowers with non-public info may assist the investigation or benefit from the SEC Whistleblower program.